Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
59.6 USD | +6.35% | +7.31% | -24.52% |
May. 30 | JPMorgan Adjusts Price Target on CVS Health to $86 From $101 | MT |
May. 30 | Baird Initiates CVS Health With Neutral Rating, $61 Price Target | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- With a P/E ratio at 10.52 for the current year and 8.88 for next year, earnings multiples are highly attractive compared with competitors.
- The stock, which is currently worth 2024 to 0.34 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.52% | 74.82B | B- | ||
+25.52% | 88.99B | C+ | ||
-0.35% | 25.03B | C+ | ||
+4.31% | 17.88B | A- | ||
-14.25% | 16.43B | B | ||
+2.97% | 15.77B | A- | ||
+79.20% | 13.21B | C+ | ||
+70.11% | 13.08B | C- | ||
+40.44% | 12.9B | B- | ||
+24.51% | 12.7B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CVS Stock
- Ratings CVS Health Corporation